Alexion drug discovery news

ALXN formed Arradial Inc. (Boston, Mass.) to commercialize ALXN's desktop silicon-based microarray assay technology for drug discovery. Arradial will receive an exclusive global license to ALXN's microarray technology in return for a licensing fee. ALXN, which retains rights to the technology to discover therapeutic antibodies, will be a minority shareholder in Arradial. Boston University, where the technology was invented, also will be a minority shareholder. ...